For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
To compare the usual treatment alone to using uproleselan plus the usual treatment.
DiagnosisAcute Myeloid Leukemia
No prior chemotherapy for MDS or AML
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Group 1: Daunorubicin + Cytarabine (usual approach group)
- Group 2: Daunorubicin + Cytarabine + Uproleselan (study drug)
Patients will either get the usual treatment or the usual treatment plus the study drug for up to 5 months. After treatment is finished the doctor will continue to follow up and watch for side effects for up to 5 years.
For more information, visit the U.S. National Library of Medicine clinical trial database.